<DOC>
	<DOC>NCT02873650</DOC>
	<brief_summary>To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.</brief_summary>
	<brief_title>Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>All females must be of nonchildbearing potential Other than hepatic impairment, subjects should be in good health as determined by no clinically significant findings from medical history, physical exam, and laboratory evaluations Subjects must have a BMI between 18.0 kg/m2 and 36 kg/m2, with a body weight of at least 50 kg and no more than 120 kg Additional criteria for hepatic impairment subjects: Subjects must have stable ChildPugh status in the past 28 days prior to dosing Additional criteria for healthy matched subjects: Matched to at least 1 hepatic impairment subject by age (+/10 years), gender and weight (+/10%) Significant acute illness within the two weeks prior to dosing History or presence of clinically significant ECG abnormalities or a family history or presence of prolonged QTinterval syndrome History or current diagnosis of cardiac disease indicating significant risk of safety for subjects participating in the study such as uncontrolled or significant cardiac disease Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs. History of malignancy of any organ system, treated or untreated, within 5 years, regardless of where there is recurrence or metastases. Healthy subjects: History of drug or alcohol abuse within 6 months prior to dosing or evidence of such abuse as indicated by laboratory values at screening or baseline. Additional exclusion for hepatic impairment subjects: History of drug or alcohol abuse within 1 month prior to dosing or evidence of such abuse as indicated by laboratory values at screening or baseline. Subject has received a liver transplant Encephalopathy Grade 3 or worse within 28 days of dosing Subjects requiring tapping more than every 3 months for the management of ascites History of surgical portosystemic shunt Subjects with clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG or laboratory evaluation. Other protocoldefined inclusion/exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Healthy volunteers</keyword>
	<keyword>Clinical pharmacology study</keyword>
	<keyword>DRB436</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>normal hepatic function</keyword>
	<keyword>impaired hepatic function</keyword>
</DOC>